Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "— Shelby Livingston"


3 mentions found


AetionAetion's website. AetionPicked by: Lynne Chou O'Keefe, the founder and managing partner of Define VenturesWhat the company does: Aetion provides pharmaceutical companies, payers, and regulators with real-world evidence they can use to inform decisions. Aetion provides the real-world evidence that insurers, pharmaceutical companies, and regulatory agencies need to evaluate the value of drugs and inform those conversations, she said. "The cost of specialty drugs, what's happening in the Inflation Reduction Act — all are bellwethers that we need a more value-based-oriented system around therapeutics going forward," she said. — Shelby Livingston
Persons: Aetion, Lynne Chou O'Keefe, O'Keefe, — Shelby Livingston
The market downturn will create opportunities for more M&A, Devin Carty, the CEO of Martin Ventures, saysDevin Carty. Martin VenturesIf 2021 was the year of big venture checks and wildly oversize valuations among healthcare startups, 2022 was when it all came crashing back to earth. But the down economy will be an opportunity for venture-capital and private-equity firms, said Carty. His Nashville, Tennessee, venture-capital firm invests in and launches healthcare startups, including companies transforming primary care, such as Wellvana, or kidney care, such as Evergreen Nephrology. So far in 2022, the firm invested in six new companies and nine startups already in its portfolio.
The market downturn will create opportunities for more M&A, Devin Carty, the CEO of Martin Ventures, saysDevin Carty. Martin VenturesIf 2021 was the year of big venture checks and wildly oversize valuations among healthcare startups, 2022 was when it all came crashing back to earth. But the down economy will be an opportunity for venture-capital and private-equity firms, said Carty. His Nashville, Tennessee, venture-capital firm invests in and launches healthcare startups, including companies transforming primary care, such as Wellvana, or kidney care, such as Evergreen Nephrology. So far in 2022, the firm invested in six new companies and nine startups already in its portfolio.
Total: 3